TENAX THERAPEUTICS, INC.
For the period ended Dec 31, 2025. Filed Mar 10, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 10, 2026
TENX$1.78+5.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Table of Contents
| PART I | 3 |
|---|---|
| ITEM 1—BUSINESS | 6 |
| ITEM 1A—RISK FACTORS | 15 |
| ITEM 1B—UNRESOLVED STAFF COMMENTS | 33 |
| ITEM 1C—CYBERSECURITY | 33 |
| ITEM 2—PROPERTIES | 34 |
| ITEM 3—LEGAL PROCEEDINGS | 34 |
| ITEM 4— MINE SAFETY DISCLOSURES | 34 |
| PART II | 36 |
| ITEM 5—MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES | 36 |
| ITEM 6—RESERVED | 36 |
| ITEM 7—MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS | 36 |
| ITEM 7A—QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK | 41 |
| ITEM 8—FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA | 41 |
| ITEM 9—CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE | 41 |
| ITEM 9A—CONTROLS AND PROCEDURES | 41 |
| ITEM 9B—OTHER INFORMATION | 43 |
| ITEM 9C— DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS. | 43 |
| PART III | 44 |
| ITEM 10—DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE | 44 |
| ITEM 11—EXECUTIVE COMPENSATION | 44 |
| ITEM 12—SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS | 45 |
| ITEM 13—CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE | 45 |
| ITEM 14—PRINCIPAL ACCOUNTANT FEES AND SERVICES | 45 |
| PART IV | 46 |
| ITEM 15—EXHIBIT AND FINANCIAL STATEMENT SCHEDULES | 46 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.